Our Phase 3 clinical programs (3) and pipeline assets (4) are designed to address the leading causes of vision loss ABC: antibody biopolymer conjugate; MESI: macular edema secondary to inflammation; AMD: age-related macular degeneration; DR: diabetic retinopathy; RVO: retinal vein occlusion Retinal Vascular Diseases Glaucoma Geographic Atrophy Ocular Inflammation Macular Edema Secondary to Inflammation (MESI) ~800K 1 ~150K* Phase 3 Anti-IL-6, VEGF trap ABC ® KSI-501 Pre-clinical NLRP3i + IOP Lowering ABC ® Glaucoma “Duet” Tarcocimab Phase 3 Anti-VEGF ABC ® Pre-clinical NLRP3i + Complement inhibition ABC ® GA “Duet” Pre-IND KSI-102: anti-IL-6, anti-TNF- α KSI-103: anti-IL-6, anti-IL-1 Bispecific proteins KSI-102 & KSI-103 Estimated prevalence (US) (wet AMD, DR, RVO) 8 1. Nila Kirupaharan et al. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6510. 2. Saundankar V et al. Manag Care Spec Pharm . 2025;31(1):88-94. 3. Ehrlich JR et al. JAMA Ophthalmol. 2024;142(11):1046–1053. 4. Rein DB et al. JAMA Ophthalmol. 2022;140(12):1202–1208. 5. Lundeen EA et al. JAMA Ophthalmol. 2023;141(8):747–754. 6. Kalva, P et al. Baylor University Medical Center Proceedings , 36 (3), 335–340. *KSI-101 initial addressable population in MESI. Kodiak Data on File and shared Investor R&D Day July 2025. KSI-101 Phase 3 Anti-IL-6, VEGF trap Bispecific protein